In conclusion, our study provides a new insight that mTOR inhibitors, as an intermittent treatment, may induce sensitivity to MMAE-ADC agents in HER2-low-expressing BC, especially after disease progression following MTA multiline treatment. The gene discussed is ERBB2; the disease is breast cancer.